Pharmafile Logo
Pharmafocus logo
Advanced Search

Kite

Showing 8 posts of 8 posts found.

credit_-_daniel_leal-olivas-afp

Kite’s leukaemia cell therapy application validated by EMA

June 24, 2021
EMA, Kite, leukemia

Kite has announced that their Type II variation application for a new indication to the approved license for autologous anti-CD19-transduced …

News
FDA building

FDA approves Kite’s Yescarta therapy for follicular lymphoma

March 9, 2021
Manufacturing and Production FDA, Kite, Yescarta

The FDA has granted accelerated approval to Kite’s Yescarta treatment, a medicine for adult patients with relapsed or refractory follicular …

News

European approval for Kite’s CAR-T therapy Tecartus in elapsed or refractory mantle cell lymphoma

December 17, 2020
Sales and Marketing CAR-T, Europe, Gilead, Kite, Tecartus

Gilead-owned Kite Therapeutics has secured marketing authorisation from the European Commission for its chimeric antigen receptor (CAR) T cell therapy …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

April 6, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Boehringer Ingelheim, Kite, Nordic Nanovector, Pfizer, Roche, Sanofi, biotech, cystic fibrosis, drugs, pharma, pharmaceutical

Some of the biggest news this week concerns companies that are looking to move on parts of their business, but …

News
gilead-sciences

Gilead seals $3bn deal, hoping for off-the-shelf CAR-T

February 23, 2018
Medical Communications, Sales and Marketing CAR-T, Gilead, Kite, Sangamo Therapeutics, biotech, drugs, pharma, pharmaceutical

The expense and laborious process involved in bringing CAR-T therapies to patients was used a key reason for the high …

News
gilead-sciences

Gilead aims to claim edge with Pfizer CAR-T combo

January 18, 2018
Medical Communications, Research and Development Gilead, Kite, Yescarta, biotech, drugs, pharma, pharmaceutical

Although those in pharma often dislike any references to drugs competing with each other for market as in a ‘race’, …

News
gilead-sciences

Gilead makes $567m strategic acquisition for next-gen CAR-T

December 8, 2017
Medical Communications, Sales and Marketing CAR-T, Cell Design Labs, Gilead, Kite, biotech, drugs, pharma, pharmaceutical

It’s only four months since Gilead completed its buy-out of Kite Pharma for $11.9 billion, but it’s already moving quickly …

News
gilead-sciences

Gilead completes £11.9 billion Kite Pharma acquisition

October 5, 2017
Sales and Marketing CAR T, CAR-T, Gilead, Kite, acquisition, pharma, pharmaceuticals

Gilead has announced that it has completed its acquisition of Kite Pharma after the deal was announced on 28 August …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024